MAIA Biotechnology (MAIA) Other Non-Current Liabilities (2022 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Other Non-Current Liabilities of $1.2 million for Q1 2026, down 33.64% year-over-year from $1.9 million in Q1 2025, and down 17.08% quarter-over-quarter from $1.5 million in Q4 2025.
MAIA Biotechnology (MAIA) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Other Non-Current Liabilities for 5 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 33.64% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 33.64% YoY), while the FY2025 annual figure was $1.5 million, down 44.53% from the prior year.
- Other Non-Current Liabilities eased to $1.2 million in Q1 2026 per MAIA's latest filing, from $1.5 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $9.6 million in Q1 2024 and bottomed at $103407.0 in Q3 2023.
- Historically, Other Non-Current Liabilities has averaged $2.2 million across 5 years, with a median of $1.7 million in 2025.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 4296.91% — and 2025, when it plunged 80.52%.
- MAIA Biotechnology's Other Non-Current Liabilities stood at $245341.0 in 2022, then jumped by 777.22% to $2.2 million in 2023, then climbed by 25.02% to $2.7 million in 2024, then sank by 44.53% to $1.5 million in 2025, then slipped by 17.08% to $1.2 million in 2026.
- Business Quant data shows MAIA's Other Non-Current Liabilities at $1.2 million in Q1 2026, $1.5 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Mn |
| Mar 31, 2026 | 1.24 Mn |
| Dec 31, 2025 | 1.49 Mn |
| Sep 30, 2025 | 1.75 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Dec 31, 2024 | 2.69 Mn |
| Sep 30, 2024 | 4.02 Mn |
| Jun 30, 2024 | 5.35 Mn |
| Mar 31, 2024 | 9.57 Mn |
| Dec 31, 2023 | 2.15 Mn |
| Sep 30, 2023 | 103,407.00 |
| Jun 30, 2023 | 121,600.00 |
| Mar 31, 2023 | 245,341.00 |
| Dec 31, 2022 | 245,341.00 |
| Sep 30, 2022 | 215,705.00 |